Differences in terms of progression-free survival (PFS) and overall survival (OS) in patients treated with first-line sorafenib, sunitinib, and pazopanib for late relapsing (>5 years) renal cell carcinoma.

被引：0
|
作者：
Santoni, Matteo
Porta, Camillo
Procopio, Giuseppe
Cerbone, Linda
Basso, Umberto
De Giorgi, Ugo
Rizzo, Mimma
Ortega, Cinzia
Massari, Francesco
Iacovelli, Roberto
di Lorenzo, Giuseppe
Milella, Michele
Sabbatini, Roberto
Atzori, Francesco
De Vivo, Rocco
Berardi, Rossana
Santini, Daniele
Cascinu, Stefano
机构：
[1] Polytech Univ Marche Reg, Azienda Osped Univ, Ospedali Riuniti Umberto I GM Lancisi & G Salesi, Ancona, Italy
[2] IRCCS San Matteo Univ Hosp Fdn, Pavia, Italy
[3] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[4] San Camillo & Forlanini Hosp, Rome, Italy
[5] Ist Oncol Veneto IOV IRCCS, Padua, Italy
[6] IRCCS Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, Italy
[7] AORN Cardarelli, Naples, Italy
[8] Fdn Piemonte Oncol, Inst Canc Res & Treatment, Turin, Italy
[9] Univ Verona, Azienda Osped Univ Integrata, I-37100 Verona, Italy
[10] Univ Naples Federico II, GU Canc Sect, Naples, Italy
[11] Reg Elena Natl Canc Inst, Rome, Italy
[12] Med Oncol Univ, Modena, Italy
[13] AOC Cagliari, Struttura Complessa Oncol Med, Cagliari, Italy
[14] San Bortolo Hosp, Vicenza, Italy
[15] Univ Politecn Marche, AO Osped Riuniti, Clin Oncol Med, Ancona, Italy
[16] Univ Campus BioMed, Dept Med Oncol, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.421
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
421
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Progression-Free Survival as a Surrogate Endpoint of Overall Survival in Patients With Metastatic Renal Cell Carcinoma
    Halabi, Susan
    Rini, Brian
    Escudier, Bernard
    Stadler, Walter M.
    Small, Eric J.
    CANCER, 2014, 120 (01) : 52 - 60
  • [22] Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma
    McAlister, Renee K.
    Aston, Jonathan
    Pollack, Megan
    Du, Liping
    Koyama, Tatsuki
    Chism, David D.
    ONCOLOGIST, 2018, 23 (06): : 686 - 692
  • [23] Use of early tumor shrinkage as a response to VEGF inhibitors as a predictor of progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Gruenwald, Viktor
    Seidel, Christoph
    Fenner, Martin
    Woike, Michael
    Kalanovic, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Baseline high-sensitivity C-reactive protein to predict progression-free survival in metastatic renal cell carcinoma patients treated with first-line sunitinib
    Mizuno, Ryuichi
    Kimura, Go
    Kondo, Tsunenori
    Ueda, Takeshi
    Hara, Hidehiko
    Kishida, Takeshi
    Kume, Haruki
    Sohji, Sunao
    Hatano, Takashi
    Morita, Jun
    Kawata, Nozomu
    Matsumoto, Kazuhiro
    Ishida, Masaru
    Takahashi, Shunji
    Tanabe, Kazunari
    Nakazawa, Hayakazu
    Horie, Shigeo
    Oya, Mototsugu
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations
    Fitzgerald, Kelly N.
    Duzgol, Cihan
    Knezevic, Andrea
    Shapnik, Natalie
    Kotecha, Ritesh
    Aggen, David H.
    Carlo, Maria I.
    Shah, Neil J.
    Voss, Martin H.
    Feldman, Darren R.
    Motzer, Robert J.
    Lee, Chung -Han
    EUROPEAN UROLOGY, 2023, 83 (03) : 195 - 199
  • [26] Progression-Free and Overall Survival of First-Line Treatments for Advanced Renal Cell Carcinoma: Indirect Comparison of Six Combination Regimens
    Ossato, Andrea
    Mengato, Daniele
    Chiumente, Marco
    Messori, Andrea
    Damuzzo, Vera
    CANCERS, 2023, 15 (07)
  • [27] Progression-free survival after second line of therapy (PFS-2) for metastatic clear cell renal cell carcinoma (ccRCC) in patients treated with first-line immunotherapy combinations.
    Fitzgerald, Kelly N.
    Duzgol, Cihan
    Knezevic, Andrea
    Shapnik, Natalie
    Kotecha, Ritesh
    Aggen, David Henry
    Carlo, Maria Isabel
    Shah, Neil J.
    Voss, Martin H.
    Feldman, Darren R.
    Motzer, Robert J.
    Lee, Chung-Han
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Development and validation of a prognostic nomogram for progression-free survival in patients with advanced renal cell carcinoma treated with pazopanib
    Kattan, Michael W.
    Sternberg, Cora N.
    Mehmud, Faisal
    Bhatt, Kamal
    McCann, Lauren
    Motzer, Robert J.
    ONKOUROLOGIYA, 2015, 11 (04): : 16 - 23
  • [29] Development and Validation of a Prognostic Nomogram for Progression-Free Survival in Patients with Advanced Renal Cell Carcinoma Treated with Pazopanib
    Kattan, Michael W.
    Sternberg, Cora N.
    Mehmud, Faisal
    Bhatt, Kamal
    McCann, Lauren
    Motzer, Robert J.
    ONCOLOGY, 2015, 89 (04) : 235 - 241
  • [30] Effect of bisphosphonates (Bis) combined with sunitinib (Su) on the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC).
    Keizman, Daniel
    Ish-Shalom, Maya
    Taksey, Jason David
    Pili, Roberto
    Hammers, Hans J.
    Eisenberger, Mario A.
    Boursi, Ben
    Berger, Raanan
    Maimon, Natalie
    Gottfried, Maya
    Hayat, Henry
    Peer, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Carducci, Michael Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
12345